The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | On-body isatuximab delivery in myeloma: improving convenience and administration
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses the emerging role of the on-body injector (OBI) formulation of isatuximab in multiple myeloma treatment. Dr Ocio highlights the potential advantages of the device, including greater convenience, reduced administration time, fewer infusion-related reactions, and the possibility of outpatient or future self-administration. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The OBI for isatuximab is really a step forward in the administration of these new drugs. We know that a sub-Q is much better than IV, of course, because of convenience, because you don’t need a line, and this is also the time you spend in the infusion is good. But also the manual infusion of sub-Q sometimes you have high volumes and it’s not so convenient or easy for patients and for nurses...
The OBI for isatuximab is really a step forward in the administration of these new drugs. We know that a sub-Q is much better than IV, of course, because of convenience, because you don’t need a line, and this is also the time you spend in the infusion is good. But also the manual infusion of sub-Q sometimes you have high volumes and it’s not so convenient or easy for patients and for nurses. What we have here is that we have a proof for Isatuximab, a new device, which is really attractive because it’s, I mean, it is just you put the vial of the Isatuximab inside the device to attach and it adheres and it just you press a button and it does everything on its own it’s very convenient it’s the needle is very small it’s safe for patients also we reduce the risk of infusion related reactions so I think now that we have such a good therapeutic options with such a good efficacy now we have to evaluate a lot and to move to very convenient drugs and very convenient ways of administering the drugs. I think this would be really something very important for patients, for nurses and for the hospital. Also it would allow the outpatient administration out of the hospital, even I would say self-administration. This probably is the future, but I think this would allow many of these things, and this would be something very important. Hopefully, we will have that soon in all the Isatuximab schemes, newly diagnosed with BRD, with Castleman, with Pomalidomide. We will have all of these available for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
